Early statin therapy reduces all-cause mortality in acute hemorrhagic stroke

Investigators at National Cheng Kung University, College of Medicine and Hospital, Tainan City, Taiwan, have found that early statin therapy reduces all-cause mortality in acute hemorrhagic stroke in statin-naive patients. They presented their poster at ESC, held in August-September in Amsterdam.

They evaluated patients who were admitted in 2008 for new hemorrhagic stroke (HS) and who were without prior statin therapy.  Those patients (n=859, mean age 63 +/- 15.4 years, male 62.6%) receiving statin treatment during hospitalization or within three months after discharge were assigned to the early statin use group and the others (n=9,947, mean age 63 +/- 15.6 years,62.9% male) were defined as the control group.

During the two-year follow-up, 2116 patients met the study end point of all-cause mortality: 109 (12.7%) in early statin use group, and 2,007 (20.2%) in the control group. The patients in the early statin use group had a reduced all-cause mortality rate (adjusted hazard ratio [HR] 0.74; 95% confidence interval [CI], 0.61 to 0.90, P<0.001) when compared with the control group.